FDA-filed SPL labeling · retrieved through openFDA

Methylphenidate

Methylphenidate is a CNS stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD) across multiple formulations, and certain products are also indicated for narcolepsy.

Brand names Adhansia XrAptensio XRConcertaCotempla XR-ODTJornay Pm +11 more
Drug class ⓘ Central Nervous System Stimulant
Rx Schedule CII Forms 10 Routes Oral · Transdermal
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 94 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveSep 23, 2025
Clinical labels in scope ⓘ94
AvailabilityRx
Earliest approval/marketing year ⓘ1955
FDA-listed product records ⓘ746
Boxed warningYes
How we combine label and product data →
✓No current FDA shortage listed · checked Sep 17, 2026 🚨Recall on record · 8
Other forms & routes:
Transdermal
⭐ Methylphenidate at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Methylphenidate is an effective, widely used stimulant for treating ADHD in children, adolescents, and adults, and certain formulations also treat narcolepsy. It works well when taken as directed, but it carries a real risk of abuse and addiction, and should be used only under close medical supervision. Regular check-ins with your doctor — to monitor blood pressure, growth in kids, and mental health — are an important part of staying safe on this medication.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Methylphenidate has a high potential for abuse, misuse, and addiction. Like other CNS stimulants, it can be misused — taken in higher doses than prescribed or by routes it's not meant for (such as snorting or injection). This dramatically increases the risk of overdose and death. Before starting this medication, your prescriber should assess your personal risk for misuse. Store it safely — ideally locked away — and never share it with anyone else. Dispose of any unused medication properly. Throughout treatment, watch for signs of misuse or dependence and discuss any concerns openly with your healthcare provider.

Read the full warning on DailyMed →

📖 Methylphenidate: Patient Information Guide

A plain-language walkthrough of Methylphenidate — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Methylphenidate is a CNS stimulant approved to treat ADHD and, in some formulations, narcolepsy. Specific approvals vary by product and age group:

  • ADHD (ages 6 and older): Most formulations — including oral extended-release tablets (e.g., Concerta, Relexxii), extended-release capsules, oral solution, and chewable tablets — are approved for children 6 and up, adolescents, and (for some products) adults up to age 65.
  • ADHD in children 6–12 only: Ritalin LA (extended-release capsules), methylphenidate hydrochloride extended-release capsules (LA and standard), and methylphenidate HCl Extended-Release Capsules CD are approved specifically for children ages 6 to 12 (CD approved to age 15).
  • ADHD in patients 6–17 only: Cotempla XR-ODT (orally disintegrating tablet), methylphenidate extended-release orally disintegrating tablets, and the methylphenidate transdermal patch (Daytrana) are approved for pediatric patients ages 6 to 17.
  • ADHD in adults up to age 65: Relexxii and certain extended-release tablet formulations are approved for adults up to 65 years of age.
  • ADHD in patients 6 and older (including adults, no upper age specified): Jornay PM is approved for patients 6 years and older.
  • Narcolepsy: Some methylphenidate hydrochloride extended-release tablet formulations and the oral solution and chewable tablets are also indicated for narcolepsy.
  • Not recommended under age 6 for any formulation due to greater drug exposure and higher risk of side effects in that age group.
⚙️How it works▾

Methylphenidate works by blocking the reuptake of dopamine and norepinephrine — two key brain chemicals involved in attention, focus, and impulse control — back into the nerve cells that released them. It also increases the release of these chemicals into the space between nerve cells. The result is higher levels of both in the brain, which helps sharpen attention and reduce impulsivity and hyperactivity. Exactly why this helps ADHD is not fully understood, but the effect on these chemical pathways is thought to be central to its benefit.

Methylphenidate is a mixture of two forms (d- and l-isomers); the d-form is the more pharmacologically active one. It does not appear to significantly affect the heart's electrical rhythm at therapeutic doses, based on available data from studies of its active component.

💊How it's taken▾

The right way to take methylphenidate depends on which formulation is prescribed — they are not interchangeable on a milligram-for-milligram basis.

  • Most oral extended-release tablets and capsules: Taken once daily in the morning, with or without food. Tablets must be swallowed whole. Some capsules may be opened and sprinkled on applesauce, but never chewed or crushed.
  • Jornay PM (evening capsule): Uniquely taken in the evening — between 6:30 and 9:30 p.m. — consistently either with or without food. Can be sprinkled on applesauce.
  • Oral liquid (Quillivant XR suspension): Taken once daily in the morning; shake the bottle vigorously for at least 10 seconds before each dose. May be taken with or without food.
  • Transdermal patch (Daytrana): Applied to the hip (alternating sides) about 2 hours before the effect is needed, and removed 9 hours after application. Avoid applying external heat (heating pads, electric blankets) to the patch site.

Always follow your prescriber's instructions. Do not stop suddenly without talking to your doctor first, and never substitute one methylphenidate product for another without guidance.

🤒Side effects — in detail▾

The most common side effects vary a little between children and adults, but generally include:

  • Decreased appetite and weight loss
  • Trouble sleeping or initial insomnia
  • Headache
  • Nausea, stomach pain, or dry mouth
  • Increased heart rate or palpitations
  • Anxiety, irritability, or nervousness
  • Dizziness
  • Increased sweating

Seek prompt medical attention for more serious reactions: chest pain or fainting, new psychiatric symptoms (hallucinations, mania), prolonged or painful erections, numbness or color changes in fingers or toes, skin pigmentation loss (with the patch), or seizures. These are uncommon but require immediate evaluation.

⚠️Warnings & precautions▾
  • Abuse, misuse, and addiction: Methylphenidate is a controlled substance with a real potential for abuse. Misuse — especially snorting or injection — can cause overdose and death. Store it securely and never share it.
  • Heart risks: Avoid in anyone with structural heart defects, serious arrhythmias, coronary artery disease, or other serious cardiac conditions. Sudden death has been reported in such patients. Blood pressure and heart rate should be monitored regularly.
  • Psychiatric effects: Can trigger or worsen hallucinations, mania, aggression, or paranoia — even in people with no prior psychiatric history. Screen for bipolar disorder before starting.
  • Growth in children: Long-term use may temporarily slow height and weight gain in children. Doctors should monitor growth regularly.
  • Priapism: Prolonged, painful erections have been reported. Seek immediate medical help if this occurs.
  • Seizures: Stimulants may lower the seizure threshold. Discontinue if seizures occur.
  • Circulation problems: Peripheral vasculopathy, including Raynaud's phenomenon (pain and color changes in fingers/toes), has been reported. Tell your doctor if you notice these changes.
  • Patch-specific: The transdermal patch may cause permanent skin pigmentation loss (chemical leukoderma) or contact sensitization (skin allergy). Discontinue and contact your doctor if either occurs.
🔀What it interacts with▾

Methylphenidate has several important drug interactions to be aware of:

  • MAO inhibitors (MAOIs): Absolutely contraindicated together or within 14 days of each other — the combination can cause hypertensive crisis (a dangerous, potentially fatal spike in blood pressure).
  • Blood pressure medications: Methylphenidate can blunt their effectiveness; your doctor may need to adjust your antihypertensive dose and will monitor your blood pressure more closely.
  • Halogenated anesthetics (surgery): Do not take methylphenidate on the day of surgery involving these anesthetics — the combination can cause sudden dangerous spikes in blood pressure and heart rate.
  • Risperidone: Combining these medications may increase the risk of extrapyramidal symptoms (involuntary muscle movements or stiffness), especially when doses are changed.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Do not take if you are allergic to methylphenidate or any ingredients in the specific product.
  • Do not take if you are currently using or have used an MAOI within the past 14 days.
  • Tell your doctor about any heart disease, high blood pressure, irregular heartbeat, or a family history of sudden cardiac death.
  • Tell your doctor if you or a family member has a history of tics or Tourette's syndrome.
  • Tell your doctor about any personal or family history of bipolar disorder, depression, or psychosis.
  • Tell your doctor about any history of seizures or epilepsy.
  • Not recommended in children under 6 years of age.
  • Safety and effectiveness in adults over 65 has not been established.
  • If you are pregnant: The data on risks to the fetus are inconsistent; there is a pregnancy registry you can join (1-866-961-2388). Discuss the risks and benefits with your doctor.
  • If you are breastfeeding: Methylphenidate does pass into breast milk. Infants should be monitored for agitation, poor sleep, poor appetite, or slow weight gain. Discuss with your doctor.
🚑If you take too much▾

Taking too much methylphenidate can cause serious symptoms including rapid or irregular heartbeat, dangerously high blood pressure, agitation, confusion, hallucinations, seizures, and life-threatening high body temperature. In severe cases, it can lead to coma, stroke, or cardiac events. If an overdose is suspected, call the Poison Help line at 1-800-222-1222 or go to the nearest emergency room immediately — and if a patch was involved, remove it right away and clean the skin, as the drug can continue to absorb even after the patch is taken off.

📡Pharmacodynamics — effects in the body▾

Methylphenidate raises the levels of dopamine and norepinephrine between nerve cells by blocking their reuptake and increasing their release. This stimulates the central nervous system, improving attention and reducing impulsivity. It also increases heart rate and blood pressure modestly — on average, by a few beats per minute and a few mmHg — though some individuals may see larger increases. At therapeutic doses, it does not appear to cause meaningful changes in the heart's electrical rhythm (QT interval).

🔬Pharmacokinetics — how your body processes it▾

Methylphenidate is absorbed fairly quickly after oral dosing, though the timing and shape of drug levels in the blood depend on the formulation. Extended-release oral formulations are designed to deliver the drug in a more gradual, sustained way compared to immediate-release forms — some produce two distinct peaks of drug levels throughout the day. The drug's half-life (how long it takes the body to clear half of it) is approximately 3.5 hours in adults and adolescents. Methylphenidate is broken down mainly in the liver into an inactive metabolite and eliminated through the urine. It does not significantly accumulate in the body with once-daily dosing.

📦How to store it▾

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) . Protect from humidity.

📄 Written from Methylphenidate’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

85

Supplements & herbs that interact with Methylphenidate

85 supplements and herbal products have documented interactions with Methylphenidate in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 64
  • Minor · 15
ACTIVATED CHARCOAL Major EPHEDRA Major LITHIUM Major PEYOTE Major RAUVOLFIA VOMITORIA Major SIDA CORDIFOLIA Major 1,3-DMAA Moderate 1,3-DMBA Moderate +77 more
Every supplement checked against Methylphenidate — ranked by severity The full interaction hub: 6 major · 64 moderate · 15 minor · every one linked to its full report. Check Methylphenidate against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Methylphenidate — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is methylphenidate supposed to do for my ADHD? ▾
Methylphenidate helps boost two brain chemicals — dopamine and norepinephrine — that play a big role in attention, focus, and impulse control. When those chemicals are more available in the right parts of the brain, most people with ADHD find it easier to stay on task, manage impulsivity, and get through daily activities. It's not a cure, but for many people it makes a real, noticeable difference in functioning at school, work, and home.
Will I get addicted to this medication? ▾
Methylphenidate is a controlled substance, and it does have a real potential for abuse and dependence — that's something the FDA takes seriously enough to put a boxed warning on the label. That said, when you take it exactly as prescribed by mouth, the risk is much lower than if it's misused. The danger goes up sharply if someone takes higher doses than prescribed or uses it in unapproved ways like snorting or injecting. Keep it stored safely, never share it, and talk openly with your doctor at every visit about how it's going.
What side effects should I actually expect, and which ones mean I need to call my doctor? ▾
The most common ones — decreased appetite, some trouble sleeping, headache, and a slightly faster heartbeat — are annoying but usually manageable and tend to improve over time. For kids, watching appetite and weight is especially important. On the more serious end: call your doctor right away if you notice chest pain, a very fast or pounding heartbeat, new mood or behavior changes like paranoia or hearing things, or any unusual or prolonged painful erections. If you're using the skin patch and notice the skin losing color at or around the application site, let your doctor know promptly.
I take a medication for blood pressure. Is that a problem? ▾
It can be something to watch. Methylphenidate can raise blood pressure and heart rate a bit, which may reduce how well your blood pressure medication works. Your doctor should know you're on both and will likely monitor your blood pressure more often and may need to adjust your blood pressure medication dose. Also, if you ever need surgery, make sure the anesthesia team knows you take methylphenidate — it shouldn't be taken on the day of surgery involving certain anesthetics.
Can I take this if I'm pregnant or breastfeeding? ▾
This is an important conversation to have with your doctor. The evidence on methylphenidate during pregnancy is mixed — some studies suggest potential risks, though nothing is definitive. There is a pregnancy registry you can join to help researchers learn more (call 1-866-961-2388). If you're breastfeeding, the drug does pass into breast milk in small amounts. Your baby should be watched for signs like poor sleep, reduced appetite, or slow weight gain. Don't stop or start anything without talking to your prescriber — they'll help you weigh the benefits against the risks for your specific situation.
My child is on the skin patch — are there any special things I need to know? ▾
Yes, a few important ones. Apply the patch to the hip, rotating sides daily, about two hours before you need it to work, and take it off after nine hours (or earlier if late-day side effects are a problem). Keep the patch site away from heat sources like heating pads or electric blankets — heat increases how much drug gets absorbed through the skin, which can cause problems. Watch the skin carefully: some redness is normal, but if there's swelling, blistering, or the skin loses pigmentation (color) at or near the patch site, tell your doctor right away and stop using the patch.
Is Methylphenidate available over the counter? ▾
Methylphenidate is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
Is Methylphenidate a controlled substance? ▾
Yes — Methylphenidate is a federally controlled substance (Schedule II) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.
When was Methylphenidate first available? ▾
Methylphenidate has been available in the United States since at least 1955, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Methylphenidate? ▾
Methylphenidate is supplied by 76 manufacturers listed in the FDA NDC Directory, including Bryant Ranch Prepack, SpecGx LLC, Lannett Company, Inc..

💬 Answers drafted from Methylphenidate’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

📊Methylphenidate supplement interactions85 checked — ranked by severity 🌿Drug & Supplement CheckerMethylphenidate vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Methylphenidate NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Methylphenidate comes

Methylphenidate is available in 10 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Ritalin
Available strengths 7 strengths
5 mg 10 mg 18 mg 20 mg 27 mg 36 mg
Show 1 more strength Show fewer strengths
54 mg
158 FDA-listed product records ⓘ

Chewable tablet

By mouth
Available strengths 3 strengths
2.5 mg 5 mg 10 mg
37 FDA-listed product records ⓘ

Extended-release chewable tablet

By mouth
Brands QuilliChew ER
Available strengths 3 strengths
20 mg 30 mg 40 mg
12 FDA-listed product records ⓘ

Orally disintegrating tablet

By mouth
Brands Cotempla XR-ODT
Available strengths 3 strengths
8.6 mg 17.3 mg 25.9 mg
12 FDA-listed product records ⓘ

📊 Methylphenidate across the U.S. market

How Methylphenidate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

10
Dose forms ⓘ
76
Manufacturers
23
Brand names
746
FDA-listed product records ⓘ
1955
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (25) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Bryant Ranch Prepack10%
SpecGx LLC8%
Lannett Company, Inc.4%
Amneal Pharmaceuticals of New York LLC4%
Granules Pharmaceuticals Inc.4%
NextWave Pharmaceuticals, Inc4%
Other makers66%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Methylphenidate is used

A general measure of how commonly Methylphenidate is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Methylphenidate is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

5,663,940
Medicaid prescriptions filled (Q1–Q4 2025)
$786.6M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Methylphenidate prescribed? Of the 1,594 medications we measure, Methylphenidate ranks #35 by Medicaid prescriptions — more than 98% of them.

Where Methylphenidate ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #35 of 1,594
#30 Clonidine 5,852,758 Rx #31 Semaglutide 5,813,664 Rx #32 Pantoprazole 5,789,599 Rx #33 Quetiapine 5,743,048 Rx #34 Triamcinolone 5,724,276 Rx #35 Methylphenidate 5,663,940 Rx #36 Semaglutide Injection 5,616,018 Rx #37 Amoxicillin / Clavulan... 5,453,053 Rx #38 Prednisone 5,404,950 Rx #39 Montelukast 5,399,653 Rx #40 Azithromycin 5,254,152 Rx

Utilization by Methylphenidate product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 36 mg 24 hr extended release oral tablet is the most-dispensed Methylphenidate product — about 15% of these Medicaid prescriptions.

24 HR methylphenidate hydrochloride 36 MG Extended Release Oral Tablet Most dispensed

831,231 Medicaid prescriptions (Q1–Q4 2025) 15% of Methylphenidate prescriptions shown $132.3M gross reimbursement (before rebates) ≈ $159 per prescription (gross)

Summed across the 9 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091185

24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet

625,386 Medicaid prescriptions (Q1–Q4 2025) 11% of Methylphenidate prescriptions shown $86.2M gross reimbursement (before rebates) ≈ $138 per prescription (gross)

Summed across the 6 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091170

24 HR methylphenidate hydrochloride 18 MG Extended Release Oral Tablet

608,875 Medicaid prescriptions (Q1–Q4 2025) 11% of Methylphenidate prescriptions shown $79M gross reimbursement (before rebates) ≈ $130 per prescription (gross)

Summed across the 6 of 27 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091155

methylphenidate hydrochloride 10 MG Oral Tablet

548,866 Medicaid prescriptions (Q1–Q4 2025) 10% of Methylphenidate prescriptions shown $8.5M gross reimbursement (before rebates) ≈ $16 per prescription (gross)

Summed across the 10 of 40 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091150

24 HR methylphenidate hydrochloride 54 MG Extended Release Oral Tablet

542,843 Medicaid prescriptions (Q1–Q4 2025) 10% of Methylphenidate prescriptions shown $85.8M gross reimbursement (before rebates) ≈ $158 per prescription (gross)

Summed across the 6 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091210

methylphenidate hydrochloride 5 MG Oral Tablet

493,969 Medicaid prescriptions (Q1–Q4 2025) 9% of Methylphenidate prescriptions shown $6.3M gross reimbursement (before rebates) ≈ $13 per prescription (gross)

Summed across the 10 of 38 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091497

methylphenidate hydrochloride 20 MG Oral Tablet

265,914 Medicaid prescriptions (Q1–Q4 2025) 5% of Methylphenidate prescriptions shown $5.4M gross reimbursement (before rebates) ≈ $20 per prescription (gross)

Summed across the 11 of 44 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091392

24 HR methylphenidate hydrochloride 5 MG/ML Extended Release Suspension

227,841 Medicaid prescriptions (Q1–Q4 2025) 4% of Methylphenidate prescriptions shown $101.6M gross reimbursement (before rebates) ≈ $446 per prescription (gross)

Summed across the 4 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1312583

24 HR methylphenidate hydrochloride 20 MG Chewable Extended Release Oral Tablet

97,766 Medicaid prescriptions (Q1–Q4 2025) 2% of Methylphenidate prescriptions shown $35.5M gross reimbursement (before rebates) ≈ $363 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1727443

30/70 Release 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule

84,328 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $4.4M gross reimbursement (before rebates) ≈ $52 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806187

8 HR methylphenidate hydrochloride 20 MG Extended Release Oral Tablet

81,698 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $2.4M gross reimbursement (before rebates) ≈ $30 per prescription (gross)

Summed across the 3 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091225

30/70 Release 24 HR methylphenidate hydrochloride 10 MG Extended Release Oral Capsule

81,026 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $3.9M gross reimbursement (before rebates) ≈ $48 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806181

methylphenidate hydrochloride 1 MG/ML Oral Solution

80,958 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $3M gross reimbursement (before rebates) ≈ $37 per prescription (gross)

Summed across the 4 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091341

50/50 Release 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule

78,140 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $6M gross reimbursement (before rebates) ≈ $76 per prescription (gross)

Summed across the 5 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806177

Evening Dosing 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule

73,812 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $32.8M gross reimbursement (before rebates) ≈ $444 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168857

24 HR methylphenidate hydrochloride 30 MG Chewable Extended Release Oral Tablet

71,279 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $27.7M gross reimbursement (before rebates) ≈ $388 per prescription (gross)

Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1734928

Evening Dosing 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule

68,849 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $30.2M gross reimbursement (before rebates) ≈ $439 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168868

8 HR methylphenidate hydrochloride 10 MG Extended Release Oral Tablet

65,321 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $1.8M gross reimbursement (before rebates) ≈ $27 per prescription (gross)

Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091145

30/70 Release 24 HR methylphenidate hydrochloride 30 MG Extended Release Oral Capsule

62,468 Medicaid prescriptions (Q1–Q4 2025) 1% of Methylphenidate prescriptions shown $3.3M gross reimbursement (before rebates) ≈ $52 per prescription (gross)

Summed across the 4 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806189

Evening Dosing 24 HR methylphenidate hydrochloride 80 MG Extended Release Oral Capsule

56,175 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $25M gross reimbursement (before rebates) ≈ $446 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168861

50/50 Release 24 HR methylphenidate hydrochloride 30 MG Extended Release Oral Capsule

55,518 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $4.7M gross reimbursement (before rebates) ≈ $84 per prescription (gross)

Summed across the 6 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806179

30/70 Release 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule

48,864 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $2.7M gross reimbursement (before rebates) ≈ $55 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806191

50/50 Release 24 HR methylphenidate hydrochloride 10 MG Extended Release Oral Capsule

48,264 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $5.9M gross reimbursement (before rebates) ≈ $121 per prescription (gross)

Summed across the 5 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806195

BX Rating 24 HR methylphenidate hydrochloride 18 MG Extended Release Oral Tablet

44,619 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $2.4M gross reimbursement (before rebates) ≈ $55 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001564

24 HR methylphenidate hydrochloride 40 MG Chewable Extended Release Oral Tablet

42,188 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $15.7M gross reimbursement (before rebates) ≈ $372 per prescription (gross)

Summed across the 1 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1734951

Evening Dosing 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule

40,287 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $17.8M gross reimbursement (before rebates) ≈ $441 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168866

BX Rating 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet

39,941 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $42 per prescription (gross)

Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001565

Evening Dosing 24 HR methylphenidate hydrochloride 100 MG Extended Release Oral Capsule

38,285 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $17.2M gross reimbursement (before rebates) ≈ $448 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168864

methylphenidate hydrochloride 2 MG/ML Oral Solution

37,648 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $2M gross reimbursement (before rebates) ≈ $53 per prescription (gross)

Summed across the 4 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091133

BX Rating 24 HR methylphenidate hydrochloride 36 MG Extended Release Oral Tablet

31,688 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1.5M gross reimbursement (before rebates) ≈ $48 per prescription (gross)

Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001566

50/50 Release 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule

31,612 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $2.7M gross reimbursement (before rebates) ≈ $86 per prescription (gross)

Summed across the 6 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806183

BX Rating 24 HR methylphenidate hydrochloride 54 MG Extended Release Oral Tablet

22,801 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1.1M gross reimbursement (before rebates) ≈ $49 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001568

30/70 Release 24 HR methylphenidate hydrochloride 50 MG Extended Release Oral Capsule

21,779 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1.3M gross reimbursement (before rebates) ≈ $59 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806193

methylphenidate hydrochloride 5 MG Chewable Tablet

21,291 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $2.3M gross reimbursement (before rebates) ≈ $106 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091322

30/70 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule

15,598 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1M gross reimbursement (before rebates) ≈ $66 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806197

24 HR methylphenidate hydrochloride 72 MG Extended Release Oral Tablet

13,935 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $6.4M gross reimbursement (before rebates) ≈ $456 per prescription (gross)

Summed across the 4 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1995461

methylphenidate hydrochloride 10 MG Chewable Tablet

10,867 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $153 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091152

methylphenidate hydrochloride 2.5 MG Chewable Tablet

9,804 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $660,590 gross reimbursement (before rebates) ≈ $67 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091389

24 HR methylphenidate hydrochloride 45 MG Extended Release Oral Tablet

6,290 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $3.1M gross reimbursement (before rebates) ≈ $492 per prescription (gross)

Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2605798

methylphenidate 25.9 MG Disintegrating Oral Tablet

5,951 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $3.8M gross reimbursement (before rebates) ≈ $643 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926849

methylphenidate 17.3 MG Disintegrating Oral Tablet

5,517 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $3.6M gross reimbursement (before rebates) ≈ $649 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926840

9 HR methylphenidate 1.11 MG/HR Transdermal System

3,264 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $831,015 gross reimbursement (before rebates) ≈ $255 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753436

9 HR methylphenidate 1.67 MG/HR Transdermal System

2,905 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $685,046 gross reimbursement (before rebates) ≈ $236 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753438

9 HR methylphenidate 2.22 MG/HR Transdermal System

2,538 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $690,805 gross reimbursement (before rebates) ≈ $272 per prescription (gross)

Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753440

methylphenidate 8.6 MG Disintegrating Oral Tablet

2,370 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $1.3M gross reimbursement (before rebates) ≈ $540 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926853

40/60 Release 24 HR methylphenidate hydrochloride 50 MG Extended Release Oral Capsule

1,835 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $275,225 gross reimbursement (before rebates) ≈ $150 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806204

24 HR methylphenidate hydrochloride 63 MG Extended Release Oral Tablet

1,810 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $955,935 gross reimbursement (before rebates) ≈ $528 per prescription (gross)

Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2605796

9 HR methylphenidate 3.33 MG/HR Transdermal System

1,713 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $480,938 gross reimbursement (before rebates) ≈ $281 per prescription (gross)

Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753441

40/60 Release 24 HR methylphenidate hydrochloride 30 MG Extended Release Oral Capsule

1,412 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $156,158 gross reimbursement (before rebates) ≈ $111 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806206

50/50 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule

1,354 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $355,825 gross reimbursement (before rebates) ≈ $263 per prescription (gross)

Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806185

40/60 Release 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule

1,255 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $195,872 gross reimbursement (before rebates) ≈ $156 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806210

40/60 Release 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule

1,210 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $241,623 gross reimbursement (before rebates) ≈ $200 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806202

40/60 Release 24 HR methylphenidate hydrochloride 15 MG Extended Release Oral Capsule

1,159 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $117,887 gross reimbursement (before rebates) ≈ $102 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1648183

40/60 Release 24 HR methylphenidate hydrochloride 10 MG Extended Release Oral Capsule

1,083 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $146,976 gross reimbursement (before rebates) ≈ $136 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806200

40/60 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule

540 Medicaid prescriptions (Q1–Q4 2025) <1% of Methylphenidate prescriptions shown $93,379 gross reimbursement (before rebates) ≈ $173 per prescription (gross)

Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806208

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Methylphenidate, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 177 of 448 listed Methylphenidate NDCs with Medicaid activity.

🔍 Compare Methylphenidate products

A representative set of FDA-listed product records for Methylphenidate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 200 of 746 products — FDA National Drug Code Directory. See every product, package size and price: browse all 746 Methylphenidate NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Methylphenidate RxCUI 6901 9 dose forms · 56 strengths
  3. Dose form (SCDF) Disintegrating Oral Tablet RxCUI 1926839 In current FDA listings
    Clinical drug / strength (SCD) 8.6 MG RxCUI 1926853 17.3 MG RxCUI 1926840 25.9 MG RxCUI 1926849
  4. Dose form (SCDF) Extended Release Oral Capsule RxCUI 374655 In current FDA listings
    Clinical drug / strength (SCD) Evening Dosing 24 HR methylphenidate hydrochloride 100 MG RxCUI 2168864 Evening Dosing 24 HR methylphenidate hydrochloride 20 MG RxCUI 2168866 Evening Dosing 24 HR methylphenidate hydrochloride 40 MG RxCUI 2168868 Evening Dosing 24 HR methylphenidate hydrochloride 60 MG RxCUI 2168857 Evening Dosing 24 HR methylphenidate hydrochloride 80 MG RxCUI 2168861 30/70 Release 24 HR methylphenidate hydrochloride 10 MG RxCUI 1806181 30/70 Release 24 HR methylphenidate hydrochloride 20 MG RxCUI 1806187 30/70 Release 24 HR methylphenidate hydrochloride 30 MG RxCUI 1806189 30/70 Release 24 HR methylphenidate hydrochloride 40 MG RxCUI 1806191 30/70 Release 24 HR methylphenidate hydrochloride 50 MG RxCUI 1806193 30/70 Release 24 HR methylphenidate hydrochloride 60 MG RxCUI 1806197 40/60 Release 24 HR methylphenidate hydrochloride 10 MG RxCUI 1806200 40/60 Release 24 HR methylphenidate hydrochloride 15 MG RxCUI 1648183 40/60 Release 24 HR methylphenidate hydrochloride 20 MG RxCUI 1806202 40/60 Release 24 HR methylphenidate hydrochloride 30 MG RxCUI 1806206 40/60 Release 24 HR methylphenidate hydrochloride 40 MG RxCUI 1806210 40/60 Release 24 HR methylphenidate hydrochloride 50 MG RxCUI 1806204 40/60 Release 24 HR methylphenidate hydrochloride 60 MG RxCUI 1806208 50/50 Release 24 HR methylphenidate hydrochloride 10 MG RxCUI 1806195 50/50 Release 24 HR methylphenidate hydrochloride 20 MG RxCUI 1806177 50/50 Release 24 HR methylphenidate hydrochloride 30 MG RxCUI 1806179 50/50 Release 24 HR methylphenidate hydrochloride 40 MG RxCUI 1806183 50/50 Release 24 HR methylphenidate hydrochloride 60 MG RxCUI 1806185
  5. Dose form (SCDF) Extended Release Oral Tablet RxCUI 372862 In current FDA listings
    Clinical drug / strength (SCD) BX Rating 24 HR methylphenidate hydrochloride 18 MG RxCUI 2001564 BX Rating 24 HR methylphenidate hydrochloride 27 MG RxCUI 2001565 BX Rating 24 HR methylphenidate hydrochloride 36 MG RxCUI 2001566 BX Rating 24 HR methylphenidate hydrochloride 54 MG RxCUI 2001568 8 HR methylphenidate hydrochloride 10 MG RxCUI 1091145 8 HR methylphenidate hydrochloride 20 MG RxCUI 1091225 24 HR methylphenidate hydrochloride 18 MG RxCUI 1091155 24 HR methylphenidate hydrochloride 27 MG RxCUI 1091170 24 HR methylphenidate hydrochloride 36 MG RxCUI 1091185 24 HR methylphenidate hydrochloride 45 MG RxCUI 2605798 24 HR methylphenidate hydrochloride 54 MG RxCUI 1091210 24 HR methylphenidate hydrochloride 63 MG RxCUI 2605796 24 HR methylphenidate hydrochloride 72 MG RxCUI 1995461

Look up RxCUI 6901 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Adhansia Xr Aptensio XR Concerta Cotempla XR-ODT Jornay Pm Metadate Cd Methylin QuilliChew ER Quillivant XR Ritalin LA Metadate ER Methylin ER Ritalin Ritalin SR Metadate Quillivant

🏭 Manufacturers & labelers

Bryant Ranch Prepack 65 SpecGx LLC 48 Lannett Company, Inc. 28 Amneal Pharmaceuticals of New York LLC 27 Granules Pharmaceuticals Inc. 25 NextWave Pharmaceuticals, Inc 24 Sun Pharmaceutical Industries, Inc. 23 Actavis Pharma, Inc. 22 Novartis Pharmaceuticals Corporation 21 Lupin Pharmaceuticals,Inc. 19 AvPAK 18 American Health Packaging 18 Societal CDMO Gainesville, LLC 18 Trigen Laboratories, LLC 16 Sandoz Inc 15 Ironshore Pharmaceuticals Inc. 15 Teva Pharmaceuticals USA, Inc. 15 Rhodes Pharmaceuticals 14 KVK-Tech, Inc. 14 Mayne Pharma 14 Janssen Pharmaceuticals, Inc. 12 Golden State Medical Supply, Inc. 12 Noven Therapeutics, LLC 12 Vertical Pharmaceuticals, LLC 12

…and 16 more on the FDA NDC directory.

RxNorm drug class

Methylphenidate belongs to the Central Nervous System Stimulant class.

Pharmacologic class Central Nervous System Stimulant
Drug family (ATC) Centrally acting sympathomimetics

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Sep 23, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Methylphenidate.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Methylphenidate after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
94
NDC products indexed
746
Distinct labelers/manufacturers represented
76
Linked representative label ⓘ
Sandoz Inc
Linked label effective
Sep 23, 2025
Composite sections available
27
Linked SPL Set ID
44386394-d2a3-4483-abe1-6c5c634cc501
Linked SPL Document ID
ade65b90-a3e4-4df4-a066-b72f161dc306
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 94 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Sandoz Inc is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.